Forbes -
15 Mar 2013 20:23
Onyx Pharmaceuticals (ONXX) had its estimates increased though 2015 by Goldman Sachs (GS) as new products in the pipeline should drive growth during the next several quarters. A $105 price target was set with a buy rating.
Share this Article